PRESENTATION

Q2 2024 — Presentation

Q2 2024PDF · 13 pages194 KB
Elevance Health
2Q 2024 Earnings Presentation
July 17, 2024

-- 1 of 13 --

2
Key Highlights
• 	Elevance Health second quarter results reflect disciplined execution of our strategic initiatives during a
dynamic time for the industry
• 	2Q 2024 adjusted diluted EPS of $10.12 grew 12% year-over-year
• 	2Q 2024 adjusted operating gain of $2.8B grew 6% year-over-year
2Q 2024 Results
1
• 	Reaffirmed 2024 adjusted diluted EPS guidance of at least $37.20, reflecting growth of 12% year-over-year
• 	Continue to optimize our Health Benefits segment through ongoing margin recovery from pandemic-era
lows in our commercial risk-based health plans and disciplined execution in government businesses
• 	Guidance embeds investment in strategic growth initiatives, notably in CarelonRx, as we integrate recent
acquisitions and scale key value drivers
2024 Outlook
2
• 	Executing on our enterprise strategy, to accelerate capabilities and services in Carelon by expanding and
scaling our enterprise flywheel for growth
• 	Minimizing barriers to whole health for Medicaid members impacted by eligibility redeterminations
• 	Building a sustainable Medicare Advantage business for the long-term
• 	Adjusted earnings per share growth algorithm provides a clear path to sustainable growth through upper
single digit growth in enterprise operating revenue, margin expansion from disciplined pricing and
operational transformation, and balanced capital deployment
Strategic Focus Areas
3

-- 2 of 13 --

33
Key Highlights
• 	Elevance Health second quarter
results reflect focused execution of
our enterprise strategy in a dynamic
operating environment
• 	Operating revenue of $43.2B includes
the impact of membership attrition in
Medicaid
• 	Benefit expense ratio of 86.3%
improved 10 basis points driven by
premium yields, inclusive of
disciplined commercial underwriting
• 	Adjusted operating expense ratio of
11.5% includes investment in strategic
growth initiatives, notably in
CarelonRx
• 	Adjusted operating gain grew 5.8%
driven by improved performance on
risk-based contracts in Carelon
2Q 2024 Results
Change (%/bps/$)	2Q 2023	2Q 2024	Elevance Health
(0.4%)	$43.4B	$43.2B	Operating Revenue 1
(10) bps	86.4%	86.3%	Medical Loss Ratio
50 bps	11.0%	11.5%	Adjusted Operating Expense Ratio1,2
5.8%	$2.7B	$2.8B	Adjusted Operating Gain1,2
40 bps	6.2%	6.6%	Adjusted Operating Margin 1,2
22.1%	$416M	$508M	Net Investment Income
11.9%	$9.04	$10.12	Adjusted diluted EPS2
($1.5B)3	$2.0B	$0.4B	Operating Cash Flow
1. 	See “Basis of Presentation” on slide 10 herein.
2. 	See “GAAP Reconciliation” on slides 11 and 12 herein.
3. 	Figures may not foot due to rounding.
Enterprise Results

-- 3 of 13 --

44
Key Highlights
• 	Health Benefits demonstrated the
resilience of our diversified mix of
business in the quarter
• 	Operating revenue was impacted by
declines in Medicaid membership,
partially offset by premium rate
increases to cover medical cost trends
• 	Operating gain increased 0.3%, driven
by disciplined underwriting, partially
offset by membership attrition
• 	Operating margin expanded 20 basis
points due to the recovery of
commercial margins from pandemic
era lows
• 	Membership of 45.8M reflects attrition
in Medicaid, partially offset by strong
growth in ACA health plan
membership
Change (%/bps)	2Q 2023	2Q 2024	Health Benefits
(2.2%)	$38.0B	$37.2B	Operating Revenue 1
0.3%	$2.1B	$2.1B	Operating Gain1
20 bps	5.6%	5.8%	Operating Margin 1
(4.6%)	48.0M	45.8M	Membership 2
1. 	See “Basis of Presentation” on slide 10 herein.
2. 	Health Benefits Membership for the three months ended June 30, 2023, is restated to reflect a change in BlueCard® membership to align to the Blue Cross Blue Shield
Association reporting methodology. For the three months ended June 30, 2023, BlueCard® membership has been restated lower by 17K.
Health Benefits
2Q 2024 Results

-- 4 of 13 --

55
Key Highlights
• 	Carelon delivered growth in services
while scaling key value drivers
• 	Serves as the enterprise flywheel for
growth, integrating physical,
behavioral, social and pharmacy
services to deliver whole health,
affordably
• 	CarelonRx operating revenue of $8.8
billion driven by strong external
member growth and the acquisition
of Paragon Healthcare; operating
gain of $497 million includes ongoing
investments in pharmacy home
delivery and specialty services
• 	Carelon Services operating revenue of
$4.5 billion grew 26%; operating gain
of $208 million grew over 32% driven
by improved performance on risk-
based arrangements
2Q 2024 Results
Change (%/bps)	2Q 2023	2Q 2024	Carelon
10.3%	$12.1B	$13.3B	Operating Revenue 1
8.0%	$653M	$705M	Operating Gain1
(10) bps	5.4%	5.3%	Operating Margin 1
1.0%	77.4M	78.2M	Adjusted Scripts
(1.3%)	103.6M	102.3M	Consumers Served
1. 	See “Basis of Presentation” on slide 10 herein.
Health Services

-- 5 of 13 --

66
Flywheel Supports Our Long-Term Growth Algorithm
Health Benefits
Optimize
the Core
Invest in
Growth
Accelerate
Targeting at least 12% average annual growth in
Adjusted Diluted Earnings Per Share
Approximately 46M medical members
balanced across commercial,
Medicaid and Medicare, leveraging
the assets and capabilities of Carelon
to accelerate growth
Integrated portfolio of whole health
solutions connecting care across
physical, behavioral, social, and
pharmacy needs to bend the cost
curve, enhance consumer experiences,
and deliver whole health, affordably
Health Services

-- 6 of 13 --

77
Adjusted Operating Gain – Upper Single Digit to Low Double Digit CAGR 1
Long-Term Growth Algorithm
Revenue Growth
Upper Single Digit CAGR 1
Adjusted Operating Margin
Expanding to 6.5% - 7.0% by 2027
Capital Deployment
Approximately 4% Contribution to
Adjusted Diluted EPS CAGR 1
Health Benefits
Mid to Upper Single Digit CAGR
Driven by membership growth, cost trend, geographic
expansion, and growth in specialized populations
Carelon Services
Upper Teens to Low Twenties CAGR
Driven by risk-based revenue growth including M&A
CarelonRx
Low-Double Digit CAGR
Driven by script volumes and drug mix
Transforming our business
processes by leveraging new
technologies across operations
Commitment to operating
efficiency and optimizing core
businesses
Effective medical management
Underwriting discipline
Share Repurchases
Organic Reinvestment
Programmatic M&A targeting
integrated solutions that
strengthen health plan
competitiveness
+ 	+
Targeting at least 12% average annual growth in Adjusted Diluted EPS
1. 	CAGR = Compound Annual Growth Rate Target.

-- 7 of 13 --

88
Committed to Strong Growth Over the Long-Term
M&A/ Organic
Reinvestment
50%
Share
Repurchase
30%
Dividends
20%
5.3%
6.5% – 7.0%
2022 	2027
Target
$156B
Upper Single
Digit CAGR2,3
2022 	2027
Target
Elevance Health
5.8%
Mid to Upper
Single Digit
2022 	2027
Target
$41B
Mid Teens
CAGR2,3
2022 	2027
Target
Carelon 4
4.3%
5.5% – 6.5%
2022 	2027
Target
$138B
Mid to Upper
Single Digit
CAGR2,3
2022 	2027
Target
Health Benefits
Capital
Allocation
Targeting at least 12% average annual
growth in Adjusted Diluted EPS
Operating
Margin 1
Revenue1
(in Billions)
1. 	2022 Operating Revenue and Operating Margin for Health Benefits, Carelon, and Elevance Health have been updated to reflect restated financials.
2. 	CAGR = Compound Annual Growth Rate Target.
3. 	Five-Year CAGR target for 2022 – 2027.
4. 	The CAGR target for revenue from 2022 – 2027 and the operating margin target in 2027 for Carelon includes: (i) a low double-digit revenue CAGR and 6.0% – 6.5% operating margin
target for CarelonRx, and (ii) an upper teens to low twenties revenue CAGR and mid to upper single-digit operating margin for Carelon Services.

-- 8 of 13 --

9
Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our
views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,”
“estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial
projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services;
and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our
control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place
undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other
disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect
our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof.
These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient
premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in
existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products
and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security
laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our
information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in
economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to
changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related
to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings
and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other
liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated
with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party
with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible
impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of
dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common
stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and
the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; the
effects of any negative publicity related to the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross and Blue
Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing
documents that may prevent or discourage takeovers and business combinations.

-- 9 of 13 --

10
Non-GAAP Measures and Basis of Presentation
This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and
are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures
calculated in accordance with GAAP are available on the last slide of this document.
Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set
incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of
products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible
assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of
operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in
understanding and analyzing Elevance Health’s operating and financial results.

-- 10 of 13 --

11	11
Elevance Health GAAP Reconciliation — Shareholders’ Net Income
and Shareholders’ Earnings Per Diluted Share Six Months Ended Jun 30	Three Months Ended Jun 30
Change	2023	2024	Change	2023	2024	(In millions, except per share data)
18.3%	$3,842	$4,546	24.1%	$1,853	$2,300	Shareholders' net income
Add / (Subtract):
456	278	221	162	Amortization of other intangible assets
234	246	121	85	Net losses on financial instruments
81	116	55	64	Transaction and integration related costs1
3	11	2	9	Litigation and settlement expenses1
—	—	—	4	Business optimization charges 1
—	(240)	—	(240)	Gain on sale of business
(200)	(103)	(103)	(22)	Tax impact of non-GAAP adjustments
574	308	296	62	Net adjustment items
9.9%	$4,416	$4,854	9.9%	$2,149	$2,362	Adjusted shareholders' net income
20.7%	$16.10	$19.44	26.4%	$7.79	$9.85	Shareholders’ earnings per diluted share
Add / (Subtract):
1.91	1.19	0.93	0.69	Amortization of other intangible assets
0.98	1.05	0.51	0.36	Net losses on financial instruments
0.34	0.50	0.23	0.27	Transaction and integration related costs1
0.01	0.05	0.01	0.04	Litigation and settlement expenses1
—	—	—	0.02	Business optimization charges 1
—	(1.03)	—	(1.03)	Gain on sale of business
(0.84)	(0.44)	(0.43)	(0.09)	Tax impact of non-GAAP adjustments
2.40	1.32	1.25	0.27	Net adjustment items
12.2%	$18.50	$20.76	11.9%	$9.04	$10.12	Adjusted shareholders’ earnings per diluted share
Six Months Ended Jun 30	Three Months Ended Jun 30
Change	2023	2024	Change	2023	2024	(In millions)
17.1%	$5,060	$5,925	22.3%	$2,441	$2,986	Income before income tax expense
(803)	(973)	(416)	(508)	Net investment income
—	(240)	—	(240)	Gain on sale of business
234	246	121	85	Net losses on financial instruments
512	545	261	280	Interest expense
456	278	221	162	Amortization of other intangible assets
5.9%	$5,459	$5,781	5.2%	$2,628	$2,765	Reportable segments operating gain
1. 	Adjustment item resides in the Corporate & Other reportable segment.

-- 11 of 13 --

12	12
Elevance Health GAAP Reconciliation — Operating Gain, Operating
Expense Ratio, and 2024 Outlook
Six Months Ended Jun 30	Three Months Ended Jun 30
Change	2023	2024	Change	2023	2024	(In millions)
3.5%	$9,618	$9,952	5.1%	$4,818	$5,066	Operating expense
Add / (Subtract):
(81)	(116)	(55)	(64)	Transaction and integration related costs1
(3)	(11)	(2)	(9)	Litigation and settlement expenses1
—	—	—	(4)	Business optimization charges 1
(84)	(127)	(57)	(77)	Net adjustment items
3.1%	$9,534	$9,825	4.8%	$4,761	$4,989	Adjusted operating expense
0.3%	$85,275	$85,496	(0.4%)	$43,377	$43,223	Operating revenue
30 bp	11.3%	11.6%	60 bp	11.1%	11.7%	Operating expense ratio
30 bp	11.2%	11.5%	50 bp	11.0%	11.5%	Adjusted operating expense ratio
Six Months Ended Jun 30	Three Months Ended Jun 30
Change	2023	2024	Change	2023	2024	(In millions)
5.9%	$5,459	$5,781	5.2%	$2,628	$2,765	Reportable segments operating gain
Add / (Subtract):
81	116	55	64	Transaction and integration related costs1
3	11	2	9	Litigation and settlement expenses1
—	—	—	4	Business optimization charges 1
84	127	57	77	Net adjustment Items
6.6%	$5,543	$5,908	5.8%	$2,685	$2,842	Reportable segments adjusted operating gain
Full Year 2024
Outlook
At least $34.05	Shareholders’ earnings per diluted share
Add / (Subtract):
$2.18	Amortization of other intangibles
$1.61	Net losses on financial instruments
$1.21	Transaction and integration related costs1
$0.07	Litigation and settlement expenses1
($1.03)	Gain on sale of business
Approximately ($0.89)	Tax impact of non-GAAP adjustments
$3.15	Net adjustment items
At least $37.20	Adjusted shareholders’ earnings per diluted share
1. 	Adjustment item resides in the Corporate & Other reportable segment.

-- 12 of 13 --



-- 13 of 13 --